Deuterated sigma-1 agonist showed anti-seizure activity in traumatic brain injury models

(The Yates Network) Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury.